San Francisco, CA – June 25, 2025 — VeriSIM Life, a leading innovator in AI-powered drug development, today announced that it has been awarded “Machine Learning Platform of the Year” in the 2025 AI Breakthrough Awards. This honor recognizes VeriSIM’s flagship platform, BIOiSIM®, for its unparalleled ability to transform drug discovery through the power of predictive modeling and translational intelligence.
San Francisco, CA – June 25, 2025 — VeriSIM Life, a leading innovator in AI-powered drug development, today announced that it has been awarded “Machine Learning Platform of the Year” in the 2025 AI Breakthrough Awards. This honor recognizes VeriSIM’s flagship platform, BIOiSIM®, for its unparalleled ability to transform drug discovery through the power of predictive modeling and translational intelligence.
San Francisco, CA – May 13, 2025 – VeriSIM Life, a trailblazer in artificial intelligence (AI)-powered drug development, is proud to announce that its Founder and CEO, Dr. Jo Varshney, has been named to the 2025 “100 Women in AI” list by Flybridge Capital Partners and XFactor Ventures.
San Francisco, CA – May 13, 2025 – VeriSIM Life, a trailblazer in artificial intelligence (AI)-powered drug development, is proud to announce that its Founder and CEO, Dr. Jo Varshney, has been named to the 2025 “100 Women in AI” list by Flybridge Capital Partners and XFactor Ventures.
San Francisco, CA – April 14, 2025 – VeriSIM Life, a leading innovator in artificial intelligence (AI) for drug development, is proud to announce that it has been honored with the "Best AI-Driven Drug Development Engine 2025 - USA" award at the prestigious Global Health & Pharma (GHP) Biotechnology & Lifesciences Awards.
San Francisco, CA – April 14, 2025 – VeriSIM Life, a leading innovator in artificial intelligence (AI) for drug development, is proud to announce that it has been honored with the "Best AI-Driven Drug Development Engine 2025 - USA" award at the prestigious Global Health & Pharma (GHP) Biotechnology & Lifesciences Awards.